Determination of Cannabinoids sativa L. samples for recreational, medical , forensic purposes for detection of ultraviolet chromatography

Since centuries, Cannabis sativa L. (C. sativa) is used for industrial purposes but it is better known as illegal drug possessing psychotropic properties. However, C. sativa is also a highly decorated medicinal plant for the use as anticancer agent, for neuroprotection and as bone marrow stimulants (Velasco et al. 2016; Machado Rocha et al. 2008). With the legalization of cannabis for therapeutic use, the demand for pure and characterized samples has grown significantly (Corroon and Phillips 2018). Therefore, currently new pharmacopeial monographs are in development for quality control of C. sativa-based medicinal products (Pavlovic et al. 2018). Besides the medical use, there is an enormous interest from consumers/patients in the utilization of low Δ9-tetrahydrocannabinol (THC) hemp for recreational use. In recent years, a kind of gold-rush fever is observed in Europe and all over the world and many new suppliers entered the market (Pellechia 2018). Since there is a complicated and different legislation for C. sativa products all over Europe, caution for quality control has to be taken. Although there is no upper limit for the cannabidiol (CBD) or cannabidiolic acid (CBDA) content in most European countries, maximum limits of THCor Δ9-tetrahydrocannabinolic acid (THCA) contents vary between 0.1 and 1% within Europe.

Determination of Cannabinoids in Cannabis sativa L. sample for recreational, medical and forensic purposes by reverse-phase liquid chromatography ultraviolet detection By “Mark Mauricio, Ramon Balmes, Lanz Mendoza”

Design a site like this with WordPress.com
Get started